###### Strengths and limitations of this study

-   This study uses a large cohort of patients sourced from the most validated UK primary care database linked to national hospital admissions data.

-   The study evaluates recording of cancer across all tumour sites.

-   As different coding systems are used in the two data sources, non-concordance may be attributed in part to the challenges in mapping different coding dictionaries.

-   The study period was limited by the coverage period of the linked cancer registry data available at the time of the study.

Introduction {#s1}
============

Over 400 million adults have diabetes worldwide, with current estimates suggesting 1 in 10 will live with the disease by 2040.[@R1] A large number of observational studies that used routinely collected electronic health records (EHRs) have evaluated the association between type 2 diabetes and various types of cancer. However, conflicting results have fuelled concerns regarding the potential for biased associations, including the misclassification of cancer outcomes.[@R2]

EHRs are increasingly used for observational studies of disease epidemiology and drug safety. The ability to accurately identify cancer events within EHRs would allow for a more valid evaluation of the relative incidences and risks of cancer outcomes in patients with type 2 diabetes, including those exposed to specific antidiabetic medications.[@R3] However, previous studies of the sensitivity, positive predictive value and agreement between different EHRs for the identification of cancer have demonstrated mixed results.[@R4] Primary care, hospital admissions and disease registry EHRs have each been shown to miss a large proportion of events in other conditions such as myocardial infarction.[@R12]

Using linked data sources for case ascertainment has been proposed in order to reduce the misclassification of outcomes.[@R12] Previous research has demonstrated reasonably high concordance between the recording of cancer diagnoses in UK primary care and linked cancer registry data,[@R13] in contrast to results from other countries.[@R15] Agreement has been shown to vary by cancer site and patient age, meaning misclassification is reduced when linked cancer registration data are used. However, the release of UK cancer registry data for research purposes is subject to time lags due to the current process of validating all the expected registrations for a given calendar year and the associated treatment and outcome information from the following 12 months prior to release.[@R16] Cancer registrations are almost exclusively based on information supplied by hospitals and from death certification.[@R13] The objective of this study was to describe the completeness of case ascertainment in the Clinical Practice Research Datalink (CPRD) primary care data linked to Hospital Episode Statistics Admitted Patient Care (HES APC) records, available more contemporaneously than linked cancer registry data. Therefore, the aims of this study were to compare the completeness of recording of cancer, date of first record, characteristics of cases most likely to be missed and relative rates (RRs) of cancer for patients with type 2 diabetes compared with patients without diabetes, across the two datasets.

Methods {#s2}
=======

Data sources {#s2a}
------------

The data used for this study were sourced from CPRD, primarily from two routinely collected linked EHR datasets.

CPRD primary care data comprise the anonymous longitudinal EHR of over 14 million patients from consenting general practitioner (GP) practices in the UK,[@R17] and have been shown in numerous validation studies to be generally of high quality.[@R19] Primary care practitioners are responsible for the management of chronic conditions including type 2 diabetes, and referrals on to specialist care, including for investigation of suspected cancer. Data contain diagnoses made in primary care and records of specialist and secondary care that have been fed back to the GP for the clinical management of the patient, coded using Read diagnosis codes. Free-text notes recorded by GPs or created from scans of letters from specialists were available to access, following anonymisation by CPRD, at the time of the study.

HES APC data include admission and discharge details of all inpatient and day-case admissions in England and Wales from 1997 onwards.[@R21] HES APC data include all diagnoses for each episode of care within a hospitalisation. The data are validated and cleaned by National Health Service (NHS) Digital at various stages in the processing cycle before derived fields are added and the data made available for research.[@R22]

In addition, this study used data from official death certificate records sourced from the Office for National Statistics, and cancer registration data sourced from the National Cancer Data Repository.

For the purposes of the current study, the source population was restricted to patients registered with GP practices participating in the CPRD linkage scheme (approximately 60%). CPRD primary care data are routinely linked to other data sources (including HES, death certificates and cancer registration data) at the patient level by NHS Digital, the trusted third party of the CPRD linkage scheme, using patient identifiers stripped from the clinical records. Records from the different data sources are deterministically linked on the basis of the unique patients NHS number, name, gender and postal code of residence. Anonymised linked data are made available to CPRD for the purposes of research, but are not provided back to the GP practices.

Study population {#s2b}
----------------

Adult patients aged 40 years and older with type 2 diabetes were identified from primary care records on the basis of one or more prescriptions for insulin or oral antidiabetic medication at least 1 year after the maximum of the patient's registration date with the GP practice and the CPRD derived start date for practice data quality (Up To Standard \[UTS\] date).[@R23] The first eligible prescription date was taken as the index date. Patients with a record of type 1 diabetes before the index date were excluded.

Each patient with type 2 diabetes was randomly matched by year of birth (within 5 years), gender and GP practice up to one patient with no records of prescriptions for insulin or oral antidiabetic medications and no records of diabetes mellitus. Matches were required to have been registered for at least 1 year before the UTS date of the same GP practice as the case at the index date of the case.

The study population was then restricted to patients from practices who participated in the linkage programme. Patients from linked practices have previously been shown to be representative of the whole CPRD population.[@R24] The study period was restricted to the overlapping coverage period of active follow-up in linked CPRD primary care, HES APC, cancer registration data and mortality data from the Office of National Statistics (April 1997 to December 2006) as recommended following previous research.[@R25] Follow-up started at the latest of the patient's index date and the start of the study period. Follow-up ended at the earliest of when a patient left the practice, the date CPRD last collected data from the practice and the end of the study period. [Figure 1](#F1){ref-type="fig"} shows the temporal relationship between cohort defining events, the index date and the outcome ascertainment period.

![Temporal relationship between cohort defining events.](bmjopen-2017-020827f01){#F1}

Cancer outcome ascertainment {#s2c}
----------------------------

Coded records of cancer were identified in CPRD primary care, HES APC, cancer registry and death certificate data independently. International Classification of Diseases 10th Revision (ICD-10) codes were used to identify cancer across HES APC, cancer registry and death certificate data (with ICD-9 being used for deaths prior to 2001), with diagnoses in primary care being made and identified using Read codes. Site-specific cancers were classified as follows: oral cavity (ICD-10 C00--14), oesophagus (C15), stomach (C16), colorectal (C18--21), pancreas (C25), head and neck (C30--32), bronchus and lung (C34), melanoma of skin (C43), non-melanoma skin cancer (NMSC) (C44), breast (C50), cervix uteri (C53), ovary (C56), prostate (C61), testis (C62), urinary organs (C64--68), brain (C71), lymphoma (C81--85), multiple myeloma (C90) or leukaemia (C91--95).

For each case recorded in CPRD primary care, it was evaluated whether HES APC contained a cancer record coded at any time, and if so, if it was of the same site. For each case recorded in HES APC, it was evaluated whether CPRD primary care contained a cancer record at any time. Coded records were searched using lists of Read code used to identify cancer outcomes in a previously published drug safety study.[@R23] If no coded record was found, the free text was searched for the following strings: carc, cancer, malign, chemoth, cytostat, oncolo, melanoma, lymphoma, leukaem, sarcom, myelom and metast. Records with a negative, such as 'cancer ruled out', were excluded. If a coded or anonymised free-text record of cancer was found, it was determined whether it was of the same site as identified in HES APC. For non-concordant cases recorded either in CPRD primary care or HES APC alone, cancer registry and death certificate data were reviewed for supporting evidence, such as registration of cancer in the cancer registry or mention of cancer anywhere on the death certificate.

The difference in time between cancer records of the same type in the two datasets was also evaluated by comparing the recorded dates of incident cancer cases.

Characteristics of missed cases {#s2d}
-------------------------------

Variables potentially associated with non-concordance between CPRD primary care and HES APC records of cancer were evaluated using multivariable logistic regression. ORs and 95% CIs were estimated for age (calculated as year of start of follow-up minus year of birth and categorised into 40--64 (reference), 65--74 and 75+), gender (females (reference) and males) and history of type 2 diabetes (patients without diabetes (reference) and patients with type 2 diabetes). Models were fitted including all three variables (age, gender and history of type 2 diabetes).

Comparison of RRs {#s2e}
-----------------

Finally, we used multivariable Poisson regression to estimate the RRs of cancer in patients with type 2 diabetes (as defined by primary care data) compared with patients without diabetes mellitus in each dataset. The objective of this analysis was to compare the RRs when cancer diagnoses were sourced from either primary care or hospital admissions data alone. These models also included covariates sourced from: (1) primary care data: age, gender, year of start of follow-up, smoking status, use of alcohol, body mass index and prescribing in the 6 months prior to the start of follow-up of angiotensin II receptor blockers, antiplatelets, beta blockers, calcium channel blockers, diuretics, nitrates, non-steroidal anti-inflammatory drugs or aspirin and statins (2) linked socioeconomic status data (measured using the quintile of the Index of Multiple Deprivation[@R26]) and (3) primary care and/or HES APCS data: medical history of coronary heart disease, coronary revascularisation, hyperlipidaemia, hypertension, peripheral vascular disease, renal impairment and stable angina. A missing data category was used for smoking status, use of alcohol and body mass index.

Reporting {#s2f}
---------

The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were used to ensure the reporting of this observational study.[@R27]

Patient and public involvement {#s2g}
------------------------------

This study uses data provided by patients and collected by the NHS as part of their care and support. \#datasaveslives

Results {#s3}
=======

The study population included 53 585 patients with type 2 diabetes matched to 47 435 patients with no record of diabetes mellitus, resulting in a total study population of 101 020 patients ([table 1](#T1){ref-type="table"}). Just over half (53% (53 672/101 020)) were male, 45% (45 243/101 020) were aged 40--64, 30% (30 348/101 020) were between 65 and 74 years and 25% (25 439/101 020) were over 75 years.

###### 

Baseline characteristics of patients with type 2 diabetes and control patients without diabetes mellitus (n=101 020)

  -------------------------------------------------------------------------------------------------------------
  Characteristic                                     Type 2 diabetes (n=53 585)   Matched controls (n=47 435)
  -------------------------------------------------- ---------------------------- -----------------------------
  Male                                               28 908 (54%)                 24 764 (52%)

  Age, by category                                                                

   40--64 years                                      24 912 (46%)                 20 331 (43%)

   65--74 years                                      15 793 (30%)                 14 555 (31%)

   75+ years                                         12 880 (24%)                 12 549 (26%)

  Body mass index                                                                 

   Underweight\                                      915 (2%)                     2399 (5%)
   (\<20  kg/m^2^)                                                                

   Normal\                                           8764 (16%)                   15 012 (32%)
   (20--25 kg/m^2^)                                                               

   Overweight\                                       19 360 (36%)                 16 209 (34%)
   (25--30 kg/m^2^)                                                               

   Obese (\>30 kg/m^2^)                              22 175 (41%)                 7292 (15%)

   Unknown                                           2371 (4%)                    6523 (14%)

  Smoking status                                                                  

   Non smoker                                        23 031 (43%)                 21 156 (45%)

   Past smoker                                       16 135 (30%)                 9738 (21%)

   Smoker                                            9488 (18%)                   9173 (19%)

   Unknown                                           4931 (9%)                    7368 (16%)

  History of:                                                                     

   Heart failure                                     3068 (6%)                    1539 (3%)

   Stable angina pectoris                            7333 (14%)                   4174 (9%)

   Coronary heart disease                            8407 (16%)                   4480 (9%)

   Hyperlipidaemia                                   3720 (7%)                    1248 (3%)

   Coronary revascularisation                        1797 (3%)                    842 (2%)

   Hypertension                                      35 325 (66%)                 19 347 (41%)

   Renal impairment                                  1051 (2%)                    486 (1%)

   Peripheral vascular disease                       2707 (5%)                    1632 (3%)

  Recent prescribing                                                              

   Organic nitrates                                  5840 (11%)                   2585 (5%)

   Beta blockers                                     11 786 (22%)                 6137 (13%)

   Calcium channel blockers                          11 774 (22%)                 5216 (11%)

   Diuretics                                         18 134 (34%)                 9640 (20%)

   Antiplatelets                                     16 980 (32%)                 7021 (15%)

   ACE inhibitors/angiotensin II receptor blockers   18 748 (35%)                 5623 (12%)

   Statins or fibrates                               17 797 (33%)                 4513 (10%)

   Non-steroidal anti-inflammatory drugs             22 415 (42%)                 12 400 (26%)
  -------------------------------------------------------------------------------------------------------------

As shown in [table 2](#T2){ref-type="table"}, 5797 patients had a coded record of cancer (excluding NMSC) in CPRD primary care. Of these cases, 83% (4835/5797) patients with a coded cancer record in primary care also had a record of cancer recorded in HES APC, with 78% (4542/5797) having the same site recorded in both data sources. The lowest level of concordance (43% (702/1106)) was found for NMSC, but all other concordance rates were 75% or above. Of the cases recorded in CPRD but not in HES APC, 56% (543/962) were present in either the cancer registry or death certificate data. Of the 318 cases recorded in HES APC but not in CPRD, 87% (278/318) were recorded in these other two datasets. Of the HES APC cases, 94% (5239/5557) were recorded in CPRD, 79% (4389/5557) indicating the same type of cancer and 11% (603/5557) mentioned in free-text alone.

###### 

Cancer recording across various data sources

                                CPRD primary care   HES APC                                                                      
  ----------------------------- ------------------- ----------- ----------- ---------- ------ ----------- ----------- ---------- ---------
  Any cancer (excluding NMSC)   5797                4835 (83)   4542 (78)   543 (9)    5557   5239 (94)   4389 (79)   603 (11)   278 (5)
  Stomach                       248                 241 (97)    138 (56)    7 (3)      229    217 (95)    139 (61)    24 (11)    11 (5)
  Colorectal                    681                 639 (94)    616 (91)    26 (4)     852    819 (96)    617 (72)    92 (11)    31 (4)
  Pancreas                      176                 156 (89)    139 (79)    16 (9)     262    246 (94)    140 (53)    37 (14)    16 (6)
  Lung                          739                 682 (92)    581 (79)    51 (7)     842    777 (92)    578 (69)    103 (12)   61 (7)
  NMSC                          1106                702 (43)    504 (31)    344 (21)   713    679 (95)    459 (64)    87 (12)    22 (3)
  Breast                        560                 474 (85)    432 (77)    63 (11)    499    487 (98)    419 (84)    13 (3)     9 (2)
  Prostate                      725                 542 (75)    517 (71)    122 (17)   593    574 (97)    447 (75)    37 (6)     14 (2)
  Urinary organs                352                 339 (96)    319 (91)    7 (2)      595    565 (95)    322 (54)    72 (12)    21 (4)
  Lymphoma                      201                 182 (91)    166 (83)    8 (4)      203    197 (97)    164 (81)    22 (11)    5 (3)
  Leukaemia                     148                 120 (81)    105 (71)    10 (7)     125    115 (92)    86 (69)     16 (13)    7 (6)

\*Percentages calculated using number of cases identified in CPRD primary care as a denominator.

†Other data sources include cancer registration and ONS mortality data.

‡Percentages calculated using number of cases identified in HES APC as a denominator.

CPRD, Clinical Practice Research Datalink; HES APC, Hospital Episode Statistics Admitted Patient Care; NMSC, non-melanoma skin cancer; ONS, Office for National Statistics.

[Table 3](#T3){ref-type="table"} shows the difference in time between cancer records of the same type in CPRD primary care and HES APC data. The majority of cases were recorded within 1 month of each other. For HES APC cases, 61% (2673/4389) were recorded within 1 month in primary care and 83% (3641/4389) within 3 months. A total of 8% (382/4542) of the CPRD cases were recorded more than 1 year before the first HES APC record, whereas only 3% (128/4389) of cases were first recorded in CPRD more than 1 year after the first HES APC record.

###### 

Difference in time between same-site records of cancer (excluding NMSC) in CPRD primary care and HES APC

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference source    Comparator source   Recorded within\   Recorded within\   Recorded within\                           Recorded within\                          Recorded\                                    Recorded\
                                          1 month\           1--3 months\       4--12 months, first in reference source\   4--12 months, last in reference source\   \>1 year apart, first in reference source\   \>1 year apart, last in reference source\
                                          n (%)              n (%)              n (%)                                      n (%)                                     n (%)                                        n (%)
  ------------------- ------------------- ------------------ ------------------ ------------------------------------------ ----------------------------------------- -------------------------------------------- -------------------------------------------
  CPRD primary care   HES APC             2670 (59)          966 (21)           275(6)                                     162 (4)                                   382 (8)                                      87 (2)

  HES APC             CPRD primary care   2673 (61)          968 (22)           174 (4)                                    246 (6)                                   128 (3)                                      200 (5)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPRD, Clinical Practice Research Datalink; HES APC, Hospital Episode Statistics Admitted Patient Care; NMSC, non-melanoma skin cancer

Age was found to be positively associated with non-concordance of cancer recording ([table 4](#T4){ref-type="table"}). For cases recorded in HES APC, the OR for non-concordance with CPRD primary care was more than doubled (OR 2.2; (95% CI 1.5 to 3.2)) for patients aged 75+ compared with patients aged 40--64 years. Cases aged 75+ recorded in CPRD had a 1.6-fold increased risk of non-concordance with HES APC versus patients aged 40--64 years (OR 1.6; (95% CI 1.3 to 2.1)) for patients aged 75+.

###### 

Variables associated with non-concordance of recording of cancer (excluding NMSC)

  Source of case                      Comparator source   Variable            Adjusted OR (95% CI)\*
  ----------------------------------- ------------------- ------------------- ------------------------
  HES APC                             CPRD                Aged 40--64 years   Reference
  Aged 65--74 years                   1.4 (0.9 to 2.1)                        
  Aged 75+ years                      2.2 (1.5 to 3.2)                        
  Females                             Reference                               
  Males                               1.0 (0.8 to 1.3)                        
  Matched patients without diabetes   Reference                               
  Patients with type 2 diabetes       0.9 (0.7 to 1.1)                        
  CPRD                                HES APC             Aged 40--64 years   Reference
  Aged 65--74 years                   1.2 (0.9 to 1.5)                        
  Aged 75+ years                      1.6 (1.3 to 2.1)                        
  Females                             Reference                               
  Males                               1.0 (0.8 to 1.2)                        
  Matched patients without diabetes   Reference                               
  Patients with type 2 diabetes       1.1 (0.9 to 1.3)                        

\*Models were fitted including all three variables (age, gender and history of type 2 diabetes).

CPRD, Clinical Practice Research Datalink; HES APC, Hospital Episode Statistics Admitted Patient Care; NMSC, non-melanoma skin cancer.

The RRs of cancer for patients with type 2 diabetes compared with matched patients without diabetes mellitus, as recorded in CPRD primary care and HES APC, are shown in [table 5](#T5){ref-type="table"}. The adjusted RRs were 0.90 (95% CI 0.86 to 0.96) for cancer recorded in CPRD primary care and 0.93 (95% CI 0.88 to 0.99) for cancer recorded in HES APC. Results for all cancer types were similar for outcomes recorded in CPRD and HES APC. CIs overlapped in all cases, and contained the RR estimated from the comparator source for all cancers apart from NMSC (adjusted RR 0.76 (95% CI 0.68 to 0.84) for NMSC recorded in CPRD primary care and 0.87 (95% CI 0.74 to 1.01) for NMSC recorded in HES APC).

###### 

RRs of different types of cancer in patients with and without type 2 diabetes, by data source

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of cancer                Source    No of cancer cases in patients with type 2 diabetes   Incidence rate/1000 person-years   No of cancer cases in matched patients without diabetes mellitus   Incidence rate/1000 person-years   Age-adjusted, sex-adjusted, calendar year-adjusted RR\   Fully adjusted RR\*\
                                                                                                                                                                                                                                         (95% CI)                                                 (95% CI)
  ----------------------------- --------- ----------------------------------------------------- ---------------------------------- ------------------------------------------------------------------ ---------------------------------- -------------------------------------------------------- ----------------------
  Any cancer (excluding NMSC)   CPRD      3073                                                  1.61                               3077                                                               1.91                               0.89 (0.84 to 0.93)                                      0.90 (0.86 to 0.96)

                                HES APC   2891                                                  1.52                               2893                                                               1.79                               0.89 (0.85 to 0.94)                                      0.93 (0.88 to 0.99)

  Stomach                       CPRD      122                                                   0.06                               133                                                                0.08                               0.81 (0.63 to 1.04)                                      0.83 (0.63 to 1.09)

                                HES APC   111                                                   0.06                               127                                                                0.08                               0.79 (0.61 to 1.02)                                      0.87 (0.65 to 1.15)

  Colorectal                    CPRD      377                                                   0.19                               338                                                                0.20                               1.00 (0.86 to 1.16)                                      1.04 (0.88 to 1.22)

                                HES APC   466                                                   0.24                               417                                                                0.25                               1.01 (0.88 to 1.15)                                      1.05 (0.91 to 1.22)

  Pancreas                      CPRD      133                                                   0.07                               56                                                                 0.03                               2.16 (1.58 to 2.96)                                      3.08 (2.19 to 4.33)

                                HES APC   201                                                   0.10                               81                                                                 0.05                               2.27 (1.75 to 2.94)                                      3.17 (2.40 to 4.20)

  Lung                          CPRD      333                                                   0.17                               449                                                                0.27                               0.66 (0.57 to 0.76)                                      0.74 (0.63 to 0.87)

                                HES APC   368                                                   0.19                               509                                                                0.31                               0.64 (0.56 to 0.74)                                      0.74 (0.64 to 0.86)

  NMSC                          CPRD      811                                                   0.42                               935                                                                0.57                               0.79 (0.72 to 0.87)                                      0.76 (0.68 to 0.84)

                                HES APC   376                                                   0.19                               378                                                                0.23                               0.92 (0.79 to 1.06)                                      0.87 (0.74 to 1.01)

  Breast                        CPRD      275                                                   0.31                               313                                                                0.39                               0.80 (0.68 to 0.94)                                      0.79 (0.66 to 0.96)

                                HES APC   251                                                   0.28                               263                                                                0.33                               0.87 (0.73 to 1.03)                                      0.83 (0.68 to 1.01)

  Prostate                      CPRD      357                                                   0.34                               408                                                                0.48                               0.78 (0.68 to 0.90)                                      0.71 (0.61 to 0.83)

                                HES APC   305                                                   0.29                               336                                                                0.39                               0.82 (0.70 to 0.96)                                      0.79 (0.66 to 0.93)

  Urinary                       CPRD      207                                                   0.11                               172                                                                0.10                               1.08 (0.88 to 1.32)                                      1.07 (0.85 to 1.34)

                                HES APC   338                                                   0.17                               291                                                                0.18                               1.04 (0.89 to 1.22)                                      1.01 (0.85 to 1.21)

  Lymphoma                      CPRD      105                                                   0.05                               105                                                                0.06                               0.88 (0.67 to 1.15)                                      0.88 (0.65 to 1.19)

                                HES APC   116                                                   0.06                               94                                                                 0.06                               1.09 (0.83 to 1.43)                                      1.13 (0.83 to 1.54)

  Leukaemia                     CPRD      84                                                    0.04                               77                                                                 0.05                               0.99 (0.72 to 1.34)                                      1.04 (0.74 to 1.46)

                                HES APC   63                                                    0.03                               70                                                                 0.04                               0.80 (0.57 to 1.13)                                      0.95 (0.65 to 1.39)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Fully adjusted for age, sex, year of start of follow-up, smoking status, use of alcohol, body mass index, prescribing in the 6 months prior to the start of follow-up (angiotensin II receptor blockers, antiplatelets, beta blockers, calcium channel blockers, diuretics, nitrates, NSAIDs or aspirin and statins), Index of Multiple Deprivation and medical history (coronary heart disease, coronary revascularisation, hyperlipidaemia, hypertension, peripheral vascular disease, renal impairment and stable angina).

CPRD, Clinical Practice Research Datalink; HES APC, Hospital Episode Statistics Admitted Patient Care; NMSC, non-melanoma skin cancer; NSAIDs, non-steroidal anti-inflammatory drugs; RRs, relative rates.

Discussion {#s4}
==========

The results of this study showed a good level of concordance in cancer recording between CPRD primary care and HES APC data, overall, in relation to the timing of the first record and in patients aged less than 75 years. The comparisons of cancer outcomes among patients with type 2 diabetes and matched patients without diabetes mellitus showed similar RRs reported in each of the two EHR databases. Together with the high level of supporting evidence for non-concordant cases from the cancer registry and death certificate data, these results suggest that misclassification of cancer in both data sources is low, except for NMSC, as expected.

However, concordance was lower when restricted to looking for recording of cancer using the same site. This was largely due to the use of non-specific cancer Read codes in both primary care and hospital admissions data, which would lead to underestimates of the incidence of site-specific cancers if either data source was used in isolation. Concordance was also lower in patients aged 75 and over. This may reflect cases where the patient died shortly after a hospital diagnosis, and information was either not sent back to the GP or was not recorded in the primary care record, or alternatively where the patient died without being hospitalised for their cancer. In addition, over 10% of cases identified in HES APC were only found in the free-text primary care records. Increased data governance regulations have subsequently led to CPRD withdrawing their provision of free-text data recorded in primary care in order to further protect patient anonymity (effective April 2016). Without these free-text data available, linked HES APC data can again reduce the risk of misclassification and underestimates of cancer incidence. Due to the positive association seen between age and non-concordance, studies focusing on older age groups may especially benefit from using linked data to capture cancer outcomes.

Few studies have been conducted comparing the recording of cancer in primary care and hospital admissions data. In the UK, a recent study considered the validity and completeness of colorectal cancer diagnoses in an alternative source of primary care data compared with HES APC in a later time period (2000--2011).[@R28] While this study used the alternative methodology of positive predictive values, the conclusions for colorectal cancer were similar, with a recorded positive predictive value of 98% compared with a concordance of 91% reported here. However, one of the strengths of this study was the ability to look across all cancer sites, including NMSC.

This study was limited by the challenges involved in directly comparing different EHR data sources. By their nature, primary care and hospital admissions data are sourced from different sectors of the healthcare system, with data collected for different purposes, at different frequencies and using different coding systems. It has been reported that clinical experts can disagree on the code lists from a single dictionary and therefore, non-concordance may be attributed in part to the challenges in mapping different coding dictionaries.[@R29] While results indicate that cancer may be recorded in primary care before hospital admissions data, this may reflect GP referrals to secondary care on the basis of suspected cancer, rather than GPs recording a confirmed diagnosis earlier than other settings. The study period was limited by the coverage period of the linked cancer registry data available at the time of the study. Furthermore, linkage between CPRD and HES APC data is dependent on the accurate recording of NHS numbers. We were not able to check the error rates of recording of NHS numbers in either data source, which would have led to overestimating non-concordance. However, previous research has identified high levels of completeness and validity of NHS numbers across primary and secondary care.[@R30] As this study was based on a cohort of patients with type 2 diabetes and matched patients without diabetes mellitus, the results may not be comparable to the general population. Patients with type 2 diabetes have more contacts with health services and cancer recording may be more up to date and accurate. However, we did not find major differences in cancer recording between the cases and their matched controls. It should also be noted that there are some differences between the RRs of cancer found in this study and those reported in previous meta-analyses (eg, this study shows an overall reduced risk of cancer among patients with type 2 diabetes in contrast to an increased risk reported previously).[@R2] As this analysis was undertaken to compare the RR when cancer diagnoses were sourced from one data source alone, rather than to best estimate the RR using all available data sources, further research using linked data to optimally define the study population, outcomes and covariates is recommended.

In conclusion, a good level of concordance in cancer recording was found between CPRD primary care and HES APC data among patients with type 2 diabetes and matched controls. However, when analysis is focused on site-specific cancers, linked data have the potential to reduce misclassification and increase case ascertainment over using either data source in isolation.
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